Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Benadryl for infants

This article was originally published in The Tan Sheet

Executive Summary

Only one in 22 infants who were given Pfizer's Benadryl (diphenhydramine) to aid with sleep saw an improvement in their condition compared to three of 22 infants taking placebo, a study in the July Archives of Pediatrics & Adolescene Medicine finds. Dan Merenstein, MD, Johns Hopkins University, et al., conducted a double-blind, randomized, controlled clinical trial of the 44 children, ages 6 months to 15 months. Placebo or diphenhydramine was given to the babies 30 minutes before anticipated bed time. Parents reported on the number of night awakenings requiring parental assistance during a week of drug treatment and 2-4 weeks after its discontinuation. Secondary outcomes included parental overall happiness with sleep and improved sleep latency. The data safety monitoring board voted unanimously to stop the trial because of lack of effectiveness of diphenhydramine over placebo...

You may also be interested in...

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts